Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vivo CRISPR/Cas9 screening identifies Pbrm1 as a regulator of myeloid leukemia development in mice.

Blood advances - 26 Sept 2023

Li Bin E, Li Grace Y, Cai Wenqing, Zhu Qian, Seruggia Davide, Fujiwara Yuko, Vakoc Christopher R, Orkin Stuart H

Abstract excerpt

CRISPR/Cas9 screening approaches are powerful tool for identifying in vivo cancer dependencies. Hematopoietic malignancies are genetically complex disorders in which the sequential acquisition of somatic mutations generates clonal diversity. Over time, additional cooperating mutations may drive disease progression. Using an in vivo pooled gene editing screen of epigenetic factors in primary murine hematopoietic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR-Cas Systems
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA-Binding Proteins

Share to Gene Editing

Share to Leukemia, Myeloid

Share to Mutation

Share to Transcription Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 37428871
DOI: 10.1182/bloodadvances.2022009455
PMCID: PMC10506108

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vivo CRISPR/Cas9 screening identifies Pbrm1 as a regulator of myeloid leukemia development in mice.PMID 37428871Read ↗

Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets.Semantic proximity Read ↗

Mutant ASXL1 Drives Transcriptional Activation and Repression in Human HematopoiesisSemantic proximity Read ↗

Srsf2P95H/+ co-operates with loss of TET2 to promote myeloid bias and initiate a chronic myelomonocytic leukemia-like disease in mice.Semantic proximity Read ↗

The H3K4 methyltransferase Setd1b is essential for hematopoietic stem and progenitor cell homeostasis in miceSemantic proximity Read ↗

<i> Srsf2 <sup>P95H/+</sup> </i> co-operates with loss of TET2 to promote myeloid bias and initiate a chronic myelomonocytic leukemia like disease in miceSemantic proximity Read ↗

Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of leukemiaSemantic proximity Read ↗

Clonal expansion and myeloid leukemia progression modeled by multiplex gene editing of murine hematopoietic progenitor cells.Semantic proximity Read ↗

Epigenetic silencing of transposable elements by IRF2BP2 is a selective dependency of myeloid leukemiaSemantic proximity Read ↗

Hematopoietic stem cells acquire survival advantage by loss of RUNX1 methylation identified in familial leukemia.Semantic proximity Read ↗

Identification of mutations that cooperate with defects in B cell transcription factors to initiate leukemia.Semantic proximity Read ↗

SETBP1 overexpression acts in the place of class-defining mutations to drive FLT3-ITD-mutant AML.Semantic proximity Read ↗

A two-step <i>in vivo</i> CRISPR screen unveils pervasive RNA binding protein dependencies for leukemic stem cells and identifies ELAVL1 as a therapeutic targetSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.